[Ip-health] Indian government warned against any more CLs as it will affect investments and its image

leena menghaney leenamenghaney at gmail.com
Tue Jun 11 00:52:01 PDT 2013


Kiran Mazumdar-Shaw of Biocon who sees herself as key spokesperson of
Indian industry interprets CL provisions.

"India should be judicious while granting compulsory licenses (CL) for
patented drugs to domestic drug makers and it should be during an
emergency, pandemic or under acute drug shortage and not on the basis of
affordability".

See today's Economic Times  - India needs to show the world it respects
intellectual property rights: Kiran Mazumdar-Shaw. You can read the article
at http://tinyurl.com/qz2pf73 or
http://economictimes.indiatimes.com/news/news-by-industry/healthcare/biotech/pharmaceuticals/india-needs-to-show-the-world-it-respects-intellectual-property-rights-kiran-mazumdar-shaw/articleshow/20520898.cms

But this is a very misleading & narrow legal interpretation both under
Indian patent law and international trade rules.

She seems to be strongly lobbying the Indian government to not grant any
more CLs particularly as she feels that it will affect investments and
India's image.

Right now the Indian health ministry has recommended CLs for trastuzumab
and Dasatinib - two cancer drugs.

--
Leena Menghaney
Tel: 46573730/1, 9811365412



More information about the Ip-health mailing list